Clinical Trial Update: Reversing Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 clinical trial update investigating reversal of microvascular dysfunction in heart failure with preserved ejection fraction.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction
• Microvascular Coronary Artery Disease

Snippet

Sponsor: Montreal Heart Institute | Conditions: Heart Failure With Preserved Ejection Fraction, Microvascular Coronary Artery Disease | Phase 2, Phase 3 | Status: UNKNOWN